Rythmol, Rythmol Sr (propafenone) is a small molecule pharmaceutical. Propafenone was first approved as Rythmol on 1989-11-27. It is used to treat atrial fibrillation, cardiac arrhythmias, and supraventricular tachycardia in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. In addition, it is known to target potassium voltage-gated channel subfamily A member 5 and beta-2 adrenergic receptor.
|Trade Name||Rythmol, Rythmol Sr|
|Indication||atrial fibrillation, cardiac arrhythmias, supraventricular tachycardia|
|Drug Class||Antiarrhythmics (propafenone derivatives)|